---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-111704"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:55:25.220121+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CFO Glenn Worman resigns; Saleem Elmasri appointed as CFO of Drugs Made In America Acquisition Corp.

## Summary
- Glenn Worman resigned as CFO and principal financial & accounting officer on Oct 8, 2025; no disagreement cited.
- Saleem Elmasri appointed CFO effective Nov 17, 2025; will serve via Titan Advisory Services LLC.
- Elmasri receives $42,000/year ($3,500/month) consulting fee and 100,000 ordinary shares upon engagement.
- Elmasri is a CPA with 20 years experience, previously at PwC and as managing partner at Titan Advisory.

## SEC filing metadata
- accession: 0001213900-25-111704
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/0001213900-25-111704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/ea0265998-8k_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-111704
- JSON: https://secwatch.observer/filing/0001213900-25-111704.json
- Plain text: https://secwatch.observer/filing/0001213900-25-111704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.